Developer docs
API playgroundTry for free, no card

Search company profiles

Comphya

Full company profile

uuid0000j9s

Namestring
Comphya
Legal namestring
Comphya SA
Websiteurl
comphya.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Comphya SA is a Swiss clinical-stage medical device company, spun out of EPFL and headquartered at Innovation Park EPFL in Lausanne, that is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function and restore erectile activity in men following radical prostatectomy. The system combines three components: an implantable electrode array placed near the cavernous nerves during prostate cancer surgery, a rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold during the post-surgical nerve-recovery window. Wireless external programming enables clinicians to adjust stimulation parameters, and the system is designed to integrate into standard nerve-sparing robotic prostatectomy workflows without additional invasive procedures.

The company's primary customer segment is men who experience erectile dysfunction after radical prostatectomy and do not respond to oral PDE5 medications, with a secondary planned segment of spinal cord injury patients with neurogenic ED. Because the device is investigational and not yet approved for commercial use, Comphya currently has no product revenue; its commercialization motion is enterprise-focused, targeting academic medical centers and high-volume urology departments for hospital procurement, with near-term activity centered on clinical trial sites such as Johns Hopkins University School of Medicine (U.S.) and Royal Melbourne Hospital (Australia). Revenue, when generated post-approval, is expected to come from hardware sales of the implantable system and potentially from ongoing programming and monitoring service contracts, distributed through standard medical device supply chains.

Operationally, Comphya is venture-backed, with disclosed cumulative funding of roughly CHF 12.6 million across early grants (Venture Kick, FIT), a CHF 850K convertible loan in January 2023, a CHF 4.35M Series A first tranche in February 2025, and an oversubscribed CHF 7.5M Series A close in July 2025. Leadership combines EPFL-derived research founders with medtech operating veterans from Medtronic, BD, Carefusion, and GE Medical Systems. The company holds an FDA Investigational Device Exemption, completed first-in-human studies in Australia reporting 90% erectile function recovery at nine months with no safety concerns, implanted its first patient in October 2025, and is targeting a pivotal trial in 2026 as the next major value-creating milestone.

Short descriptiontext

Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to restore erectile function in men following radical prostatectomy, with a secondary focus on spinal cord injury patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neuromodulation devices, erectile dysfunction treatment, urology medical devices, neurostimulation therapy, post-prostatectomy care
Industry3 codes
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAOAH
Reconstructive Urology & Urethral Stricture Care
SECONDARYHLAKAOAI
Neurourology & Voiding Dysfunction
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Implantable Neuromodulation Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Implantable Medical Device Sales
TypeHardware Sales
Description

Pre-commercial stage company developing an implantable neurostimulation system. Revenue will be generated from device sales to hospitals and surgical centers following regulatory approval. The system includes implantable components (electrode array and pulse generator) that would be procured through standard medical device supply chains.

comphya.com
2Neuromodulation Therapy System
TypeManaged Services
Description

Complete therapy system including implantable device, subcutaneous pulse generator, and ongoing programming/adjustment services. May include service contracts for device monitoring and programming support.

comphya.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Comphya is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function following radical prostatectomy. The system consists of three integrated components: an implantable electrode array placed during prostate cancer surgery near the cavernous nerves, a small rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold. It targets the root cause of nerve-related erectile dysfunction during the post-surgical healing window rather than managing symptoms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% erectile function recovery by 9 months in first-in-human study
+4 more records
Product overview1 text field

Comphya offers a single unified product — the CaverSTIM™ Neuromodulation System. This investigational device is an implantable system comprising three integrated components: an implantable electrode array (placed during prostate cancer surgery adjacent to cavernous nerve bundles), a subcutaneous pulse generator (rechargeable unit implanted under the skin in the lower abdomen), and a neuromodulation protocol (programmed daily stimulation routine delivered below the sensory threshold). The system is designed for placement during radical prostatectomy surgery and provides ongoing neurostimulation during the critical nerve recovery window.

Product and service1 record
1CaverSTIM™ Neuromodulation System
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Ongoing pilot clinical trial site for CaverSTIM device in the United States. FDA Investigational Device Exemption (IDE) granted for U.S. clinical evaluation. The trial is assessing safety and efficacy of the implantable neurostimulation system.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

First-in-human study completed in Australia at Royal Melbourne Hospital, demonstrating promising early signals with 90% erectile function recovery. Ongoing pilot trials continue at this site. Enhanced clinical trials initiated in Australia following Series A funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Comphya was founded as a spin-out from EPFL. The company is based at Innovation Park EPFL. Nikos Stergiopulos, Professor at EPFL and Director of the Laboratory of Hemodynamics and Cardiovascular Technology, serves as Board Member and Co-Founder. The technology is based on research conducted at EPFL.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global urology medical device company with diagnostics and therapeutics across the urology care pathway. Comparable as an incumbent in urology device distribution and as a strategic acquirer/platform for emerging urology technologies like CaverSTIM.

2Axonics
TypeDirect peer
Description

Pure-play implantable neuromodulation company with sacral and pudendal nerve stimulation systems for incontinence. Axonics is the most directly comparable peer to Comphya in terms of business model (single-platform implantable neurostim), target customer (urology specialists), and go-to-market (hospital-based implantation), though its indication is bowel/bladder rather than sexual dysfunction.

TypeBroad incumbent
Description

Global neuromodulation leader via its InterStim sacral neuromodulation system for bladder/bowel dysfunction. While addressing a different urologic indication, Medtronic's InterStim is the closest large-scale analog to CaverSTIM's implantable nerve stimulation approach and represents the dominant incumbent Comphya would eventually compete with for hospital neuromodulation infrastructure and reimbursement.

TypeEmerging player
Description

Emerging neuromodulation company with a small, coin-sized implantable tibial nerve stimulator (eCoin) for urinary incontinence. Comparable as a clinical-stage, single-product implantable neuromodulation company targeting urology indications and pursuing similar miniaturization and minimally-invasive implant positioning strategies.

TypeEmerging player
Description

Early-stage medical device incubator developing novel neuromodulation and minimally invasive therapies. Comparable as an emerging player in novel implantable device development targeting niche urologic or pelvic indications with limited treatment options.

TypeBroad incumbent
Description

Established player in male pelvic health via its penile implant (inflatable prosthesis) business for severe ED. Coloplast is the incumbent surgical treatment for ED unresponsive to medication, representing the most direct competitive threat to CaverSTIM's commercial positioning if CaverSTIM reaches the same refractory patient population.

TypeEmerging player
Description

Implantable neuromodulation company developing miniaturized, wirelessly powered neurostimulators for multiple indications including urology/pelvic pain. Comparable as a smaller emerging player focused on novel form-factor neuromodulation devices and similar clinical/regulatory pathway.

TypeEmerging player
Description

Clinical-stage company developing miniaturized, wirelessly powered implantable neuromodulation systems. Comparable as an emerging neuromodulation platform pursuing miniaturized, recharge-free or rechargeable implants and similar regulatory pathway to first-in-class implantable neurostim products.

TypeBroad incumbent
Description

Boston Scientific's Male Pelvic Health franchise (formerly American Medical Systems) markets penile implants and urology devices. Comparable as a broad incumbent in male sexual health surgical devices and as a potential strategic acquirer of novel neuromodulation technology.

TypeEmerging player
Description

Women's sexual health medical device company (Fiera) targeting intimacy and sexual wellness. Comparable thematically as a clinical-stage sexual medicine device company targeting an underserved, low-publicity patient population, although addressing the female rather than male side of sexual health.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Comphya

Implantable Neuromodulation Devicescomphya.com

Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to restore erectile function in men following radical prostatectomy, with a secondary focus on spinal cord injury patients.

What Comphya does

Comphya SA is a Swiss clinical-stage medical device company, spun out of EPFL and headquartered at Innovation Park EPFL in Lausanne, that is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function and restore erectile activity in men following radical prostatectomy. The system combines three components: an implantable electrode array placed near the cavernous nerves during prostate cancer surgery, a rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold during the post-surgical nerve-recovery window. Wireless external programming enables clinicians to adjust stimulation parameters, and the system is designed to integrate into standard nerve-sparing robotic prostatectomy workflows without additional invasive procedures.

The company's primary customer segment is men who experience erectile dysfunction after radical prostatectomy and do not respond to oral PDE5 medications, with a secondary planned segment of spinal cord injury patients with neurogenic ED. Because the device is investigational and not yet approved for commercial use, Comphya currently has no product revenue; its commercialization motion is enterprise-focused, targeting academic medical centers and high-volume urology departments for hospital procurement, with near-term activity centered on clinical trial sites such as Johns Hopkins University School of Medicine (U.S.) and Royal Melbourne Hospital (Australia). Revenue, when generated post-approval, is expected to come from hardware sales of the implantable system and potentially from ongoing programming and monitoring service contracts, distributed through standard medical device supply chains.

Operationally, Comphya is venture-backed, with disclosed cumulative funding of roughly CHF 12.6 million across early grants (Venture Kick, FIT), a CHF 850K convertible loan in January 2023, a CHF 4.35M Series A first tranche in February 2025, and an oversubscribed CHF 7.5M Series A close in July 2025. Leadership combines EPFL-derived research founders with medtech operating veterans from Medtronic, BD, Carefusion, and GE Medical Systems. The company holds an FDA Investigational Device Exemption, completed first-in-human studies in Australia reporting 90% erectile function recovery at nine months with no safety concerns, implanted its first patient in October 2025, and is targeting a pivotal trial in 2026 as the next major value-creating milestone.

Comphya firmographics

Firmographics
Name
Comphya
Legal name
Comphya SA
Website
https://comphya.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to restore erectile function in men following radical prostatectomy, with a secondary focus on spinal cord injury patients.
Ownership category
akta.pro rank

Comphya industry classification

Industry
Product category
Implantable Neuromodulation Devices
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAOAH
Reconstructive Urology & Urethral Stricture Care
SECONDARYHLAKAOAI
Neurourology & Voiding Dysfunction

Keywords

  • Implantable neuromodulation devices
  • Erectile dysfunction treatment
  • Urology medical devices
  • Neurostimulation therapy
  • Post-prostatectomy care

Where Comphya is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Comphya business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Implantable Medical Device Sales: Pre-commercial stage company developing an implantable neurostimulation system. Revenue will be generated from device sales to hospitals and surgical centers following regulatory approval. The system includes implantable components (electrode array and pulse generator) that would be procured through standard medical device supply chains.
  2. Neuromodulation Therapy System: Complete therapy system including implantable device, subcutaneous pulse generator, and ongoing programming/adjustment services. May include service contracts for device monitoring and programming support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Comphya product offering

Product offering

Core offering

Comphya is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function following radical prostatectomy. The system consists of three integrated components: an implantable electrode array placed during prostate cancer surgery near the cavernous nerves, a small rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold. It targets the root cause of nerve-related erectile dysfunction during the post-surgical healing window rather than managing symptoms.

Product overview

Comphya offers a single unified product — the CaverSTIM™ Neuromodulation System. This investigational device is an implantable system comprising three integrated components: an implantable electrode array (placed during prostate cancer surgery adjacent to cavernous nerve bundles), a subcutaneous pulse generator (rechargeable unit implanted under the skin in the lower abdomen), and a neuromodulation protocol (programmed daily stimulation routine delivered below the sensory threshold). The system is designed for placement during radical prostatectomy surgery and provides ongoing neurostimulation during the critical nerve recovery window.

Differentiator

Problem solved

Functional benefit

Products and services

  • CaverSTIM™ Neuromodulation System

Quantifiable outcome

  • 90% erectile function recovery by 9 months in first-in-human study
  • +4 more outcomes

Companies that use Comphya

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Comphya technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Comphya partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Johns Hopkins University School of MedicinecoreStrategic or Co-development Partner · 1 January 2024Ongoing pilot clinical trial site for CaverSTIM device in the United States. FDA Investigational Device Exemption (IDE) granted for U.S. clinical evaluation. The trial is assessing safety and efficacy of the implantable neurostimulation system.
  • Royal Melbourne HospitalcoreStrategic or Co-development Partner · 1 January 2021First-in-human study completed in Australia at Royal Melbourne Hospital, demonstrating promising early signals with 90% erectile function recovery. Ongoing pilot trials continue at this site. Enhanced clinical trials initiated in Australia following Series A funding.
  • EPFL (Swiss Federal Institute of Technology Lausanne)coreStrategic or Co-development Partner · 1 January 2019Comphya was founded as a spin-out from EPFL. The company is based at Innovation Park EPFL. Nikos Stergiopulos, Professor at EPFL and Director of the Laboratory of Hemodynamics and Cardiovascular Technology, serves as Board Member and Co-Founder. The technology is based on research conducted at EPFL.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Comphya competitors and assessment

Company assessment

Broad incumbents

  • Laborie Medical Technologies: Global urology medical device company with diagnostics and therapeutics across the urology care pathway. Comparable as an incumbent in urology device distribution and as a strategic acquirer/platform for emerging urology technologies like CaverSTIM.
  • Medtronic: Global neuromodulation leader via its InterStim sacral neuromodulation system for bladder/bowel dysfunction. While addressing a different urologic indication, Medtronic's InterStim is the closest large-scale analog to CaverSTIM's implantable nerve stimulation approach and represents the dominant incumbent Comphya would eventually compete with for hospital neuromodulation infrastructure and reimbursement.
  • Coloplast: Established player in male pelvic health via its penile implant (inflatable prosthesis) business for severe ED. Coloplast is the incumbent surgical treatment for ED unresponsive to medication, representing the most direct competitive threat to CaverSTIM's commercial positioning if CaverSTIM reaches the same refractory patient population.
  • Boston Scientific (Male Pelvic Health / AMS): Boston Scientific's Male Pelvic Health franchise (formerly American Medical Systems) markets penile implants and urology devices. Comparable as a broad incumbent in male sexual health surgical devices and as a potential strategic acquirer of novel neuromodulation technology.

Direct peers

  • Axonics: Pure-play implantable neuromodulation company with sacral and pudendal nerve stimulation systems for incontinence. Axonics is the most directly comparable peer to Comphya in terms of business model (single-platform implantable neurostim), target customer (urology specialists), and go-to-market (hospital-based implantation), though its indication is bowel/bladder rather than sexual dysfunction.

Emerging players

  • Valencia Technologies (eCoin): Emerging neuromodulation company with a small, coin-sized implantable tibial nerve stimulator (eCoin) for urinary incontinence. Comparable as a clinical-stage, single-product implantable neuromodulation company targeting urology indications and pursuing similar miniaturization and minimally-invasive implant positioning strategies.
  • TheraNova: Early-stage medical device incubator developing novel neuromodulation and minimally invasive therapies. Comparable as an emerging player in novel implantable device development targeting niche urologic or pelvic indications with limited treatment options.
  • Stimwave Technologies: Implantable neuromodulation company developing miniaturized, wirelessly powered neurostimulators for multiple indications including urology/pelvic pain. Comparable as a smaller emerging player focused on novel form-factor neuromodulation devices and similar clinical/regulatory pathway.
  • Neuspera Medical: Clinical-stage company developing miniaturized, wirelessly powered implantable neuromodulation systems. Comparable as an emerging neuromodulation platform pursuing miniaturized, recharge-free or rechargeable implants and similar regulatory pathway to first-in-class implantable neurostim products.
  • Nuelle: Women's sexual health medical device company (Fiera) targeting intimacy and sexual wellness. Comparable thematically as a clinical-stage sexual medicine device company targeting an underserved, low-publicity patient population, although addressing the female rather than male side of sexual health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Comphya social profiles

Digital presence

Comphya financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Comphya leadership team

Management profile

Number of profiles

Profiles8 records

Comphya funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Comphya M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comphya

What does Comphya do?

Comphya is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function following radical prostatectomy. The system consists of three integrated components: an implantable electrode array placed during prostate cancer surgery near the cavernous nerves, a small rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold. It targets the root cause of nerve-related erectile dysfunction during the post-surgical healing window rather than managing symptoms.

Is Comphya a public or private company?

Comphya is a private company. It is classified as venture growth investor backed and is currently operating.

When was Comphya founded?

Comphya was founded in 2017. It employs 1 to 10 people.

Where is Comphya based?

Comphya is headquartered in Lausanne, Switzerland, in the Europe region.

How does Comphya make money?

Two revenue lines are on record. Implantable Medical Device Sales are the primary driver. The others are neuromodulation Therapy System.

Who are Comphya's main competitors?

Broad incumbents on record are Laborie Medical Technologies, Medtronic, Coloplast and Boston Scientific (Male Pelvic Health / AMS). Axonics is listed as a direct peer. Emerging players are Valencia Technologies (eCoin), TheraNova, Stimwave Technologies, Neuspera Medical and Nuelle.

Does Comphya have an API?

No public API is recorded for Comphya.

What industry is Comphya in?

Comphya's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts), with a secondary code of HLAKAOAH, Reconstructive Urology & Urethral Stricture Care. Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VerveComphyaComphya, a Swiss biotech founded in 2019, is developing an active implantable medical device to restore erectile function in patients unresponsive to oral drugs. The device targets spinal cord injury and prostatectomy patients, aiming to replace problematic intrapenial injections or penile implants.startupticker.chSwiss medtechs report clinical progress in heart, brain, and urological healthThree Swiss medtech startups, Artiria Medical, Comphya, and Berlin Heals, have achieved key clinical milestones for their devices targeting cerebral arteries, erectile dysfunction, and heart failure, respectively. Artiria Medical has treated over 100 patients in North America with its guidewire, Comphya implanted its first patient for its nerve stimulation system, and Berlin Heals completed enrollment for its heart therapy trial. These developments mark significant progress in their respective clinical programs.Silicon CanalsSwiss-based Comphya raises €8M to restore erectile function in patients non-responsive to oral drugsComphya, a Swiss medtech firm, closed an oversubscribed Series A at CHF 7.5M (€8.07M) to advance its CaverSTIM neurostimulator for erectile dysfunction. The funds will support a U.S. pilot study at Johns Hopkins and a pivotal trial planned for 2026, following positive Australian trial results.GlobeNewswireComphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot DataComphya closed an oversubscribed Series A round, bringing total equity raised to CHF 7.5 million (~USD 8.4 million). Proceeds will fund a U.S. pilot study at Johns Hopkins and prepare for a pivotal trial in 2026. The company also plans a Series B round to support the pivotal trial.startupticker.chAdditional funding brings Comphya’s series A to CHF 7.5 millionComphya SA, a company based in Lausanne, has completed an oversubscribed Series A funding round, raising CHF 7.5 million to support clinical trials for its device, CaverSTIM, designed to treat erectile dysfunction in prostatectomy patients. The company plans to expand its studies in Australia and initiate a U.S. pilot at Johns Hopkins, with the goal of conducting a pivotal trial in 2026.startupticker.chComphya secures Series A First Tranche of CHF 4.35MComphya SA closed the first tranche of its Series A1 funding, raising CHF 4.35 million in converted loan and equity. The funds will advance clinical trials for CaverSTIM, an implantable neuromodulator for erectile dysfunction, across Australia, Brazil, and the US.startupticker.chComphya receives approval for first long-term implantation clinical trialAustralian regulatory authorities approved the pilot clinical trial for CaverSTIM in patients undergoing prostatectomy, the first long-term implantation trial of the device. The trial will assess safety and preliminary efficacy at Royal Melbourne Hospital, with implantation via robotic-assisted laparoscopic surgery. CaverSTIM is a neuromodulator for erectile dysfunction in non-responders to oral drugs.FinSMEsComphya Raises CHF 850K in Additional FundingComphya, a Lausanne-based medical device company, raised CHF 850K in additional funding through a convertible loan from existing shareholders and new investors. The financing brings the company's total raised capital to CHF 5.1M, which will be used to initiate pilot clinical trials for its CaverSTIM implantable neurostimulation device in Q1 2023.startupticker.chComphya raises funds for clinical trialsComphya SA secured a convertible loan of CHF850k, bringing its total raised funds to CHF 5.1 million to finance pilot clinical trials for its CaverSTIM neuromodulator device. The company plans to initiate these safety and efficacy trials in Q1 2023 across Australia, Brazil, the US, and France. This funding round included participation from existing shareholders, new investors, and the non-profit Praxis Spinal Cord Institute.startupticker.chComphya raises additional USD 1.3 millionComphya, a Lausanne-based developer of a neuromodulator for erectile dysfunction, raised USD 1.3 million in bridge financing. The funds will support pilot clinical trials starting early 2021 for spinal cord injury and post-prostatectomy patients. The investment includes convertible loans and a FIT Growth Loan.